HCPCS code Q5127: Stimufend injection, per 0.5 mg2026 Medicare rate & RVUs in Missouri
Reports Stimufend, a pegfilgrastim biosimilar used to reduce infection risk from chemotherapy-related neutropenia, in 0.5 mg billing units.
CMS doesn’t publish an office rate for Q5127 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What Q5127 covers
Q5127 identifies pegfilgrastim-fpgk, marketed as Stimufend, a biosimilar of pegfilgrastim. This long-acting granulocyte colony-stimulating factor is administered by subcutaneous injection to help reduce the risk of infection associated with chemotherapy-induced neutropenia. Oncology practices and other clinicians administering supportive cancer therapy may report the drug in physician offices, clinics, or hospital outpatient settings. The product-specific code distinguishes Stimufend from other pegfilgrastim products.
CMS assigns physician fee schedule status E, meaning the drug is excluded from the physician fee schedule. When Medicare covers it, payment is handled through another method; CMS classifies it as a Part B drug that is generally priced from quarterly ASP drug pricing files. The Medicare contractor determines coverage. Each Q5127 unit represents 0.5 mg of pegfilgrastim-fpgk: for example, a 6 mg administered dose corresponds to 12 units. Report the code for the Stimufend product actually administered.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where Q5127 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the Q5127 rate is calculated
Each of Q5127’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · Q5127
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for Q5127
Q5127 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · Q5127
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
Q5127 isn’t priced in this setting.
Q5127 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- Q5120Pegfilgrastim-bmezPer 0.5 mg
- Q5120 identifies pegfilgrastim-bmez; Q5127 identifies pegfilgrastim-fpgk (Stimufend). Choose according to the product administered.
- Q5130Pegfilgrastim-pbbkPer 0.5 mg
- Q5130 identifies pegfilgrastim-pbbk (Fylnetra), not Stimufend. The products have separate HCPCS codes.
- J2506Pegfilgrastim injectionPer 0.5 mg
- J2506 reports pegfilgrastim in 0.5 mg units without identifying Stimufend specifically. Q5127 identifies the pegfilgrastim-fpgk product.
Q5127 billing questions
How many Q5127 units represent a 6 mg dose?
Each unit represents 0.5 mg, so a 6 mg dose is 12 units.
Should Q5127 be used for another pegfilgrastim biosimilar?
No. Q5127 identifies pegfilgrastim-fpgk (Stimufend). Select the HCPCS code that identifies the product actually administered.
How does Medicare treat Q5127?
CMS assigns status E, excluding it from the physician fee schedule. When covered, it is a Part B drug generally priced through quarterly ASP files, with coverage left to the Medicare contractor.
Does Q5127 describe the injection administration service?
No. Q5127 identifies the drug and its administered quantity, not the administration service.
What documentation supports the reported units?
Document the Stimufend product administered and the dose given so the reported 0.5 mg units can be verified.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put Q5127 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist